Magnesium Sulfate Demo (Magnesium Sulfate Heptahydrate)

Magnesium sulfate acts as a calcium antagonist and NMDA receptor antagonist. By blocking calcium entry into cells and modulating excitatory neurotransmission, it promotes vasodilation, reduces neuronal excitability, and helps prevent seizures while supporting normal cardiac electrophysiology.

The appropriate dose of Magnesium Sulfate Demo is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goal. Dosing regimens are individualized and should follow local clinical guidelines.

Safety data for magnesium sulfate in pregnancy are limited, but it is sometimes used for seizure prophylaxis in preeclampsia when benefits outweigh risks. Use during breastfeeding is generally considered compatible, yet clinicians should evaluate each case individually.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Magnesium sulfate is unique in its dual role as a calcium antagonist and NMDA receptor blocker, offering rapid seizure control especially in obstetric emergencies. Compared with benzodiazepines or antihypertensives, it provides both neuroprotective and vasodilatory effects, though the choice depends on the clinical scenario and patient profile.

Magnesium Sulfate Demo should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Ensure the solution is kept in a clean, dry area and inspected for particulate matter before administration.

The product is administered intravenously under aseptic conditions. It is typically infused slowly using a calibrated infusion set, with the rate adjusted according to the patient’s serum magnesium levels and clinical response, as directed by the treating physician.

Serious risks include respiratory depression, severe hypotension, cardiac arrest, hypermagnesemia leading to muscle weakness or loss of reflexes, and rare anaphylactic reactions. Continuous monitoring of vital signs and serum magnesium concentrations is essential during infusion.

Patients with known hypersensitivity to magnesium sulfate, severe renal failure without dialysis capability, or uncontrolled cardiac conduction abnormalities should generally avoid the product unless a careful risk‑benefit assessment justifies its use.